Rift Valley Fever Virus Glycoproteins, GN and GC, and their Use
AssigneesThe United States Government as represented by the Secretary of Agriculture, Kansas State University Research Foundation
InventorsJuergen A. Richt, Bonto Faburay, William Wilson
Life of this patent
Estimating the term…
Abstract
The present invention describes subunit vaccines containing Gn and Gc glycoproteins of the Rift Valley Fever Virus, including nucleic acids encoding such glycoproteins, host cells, vectors, and immunoreagents generated with the glycoproteins, methods of vaccination, methods of diagnosis, and kits.
Claims20
An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:1, wherein said isolated nucleic acid molecule encodes an polypeptide or protein consisting essentially of an amino acid sequence as set forth in SEQ ID NO:
- 4 or SEQ ID NO:6.
An isolated protein or polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:4, SEQ ID NO:6, an amino acid sequence having at least 90% homology to SEQ ID NO:4 or SEQ ID NO:6, or a functional fragment of SEQ ID NO:4 or SEQ ID NO:6, wherein said polypeptide or protein does not contain a transmembrane domain, and wherein said protein or polypeptide induces neutralizing antibodies against Rift Valley Fever Virus in a subject at primary dose.
A method of vaccinating a subject in need thereof comprising administering an immunogenically effective amount of a composition comprising an isolated protein or polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:4, SEQ ID NO:6, an amino acid sequence having at least 90% homology to SEQ ID NO:
- 4 or SEQ ID NO:6, or a functional fragment of SEQ ID NO:4 or SEQ ID NO:6, wherein said polypeptide or protein does not contain a transmembrane domain, and wherein said protein or polypeptide induces neutralizing antibodies against Rift Valley Fever Virus in a subject at a primary dose.
A kit comprising:
- a) an isolated protein or polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:4, SEQ ID NO:6, an amino acid sequence having at least 90% homology to an amino acid sequence as set forth in SEQ ID NO:
- 4 or SEQ ID NO:6, or a functional fragment of an amino acid as set forth in SEQ ID NO:4 or SEQ ID NO:6, wherein said polypeptide or protein does not contain a transmembrane domain, and wherein said protein or polypeptide induces neutralizing antibodies against Rift Valley Fever Virus in a subject at primary dose;
- b) a first Rift Valley Fever Virus (RVFV)-specific immunoreagent which binds to the isolated polypeptide or protein of (a), wherein said immunoreagent is selected from the group consisting of monoclonal antibody, antibody from polyclonal sera, Fab, F(ab′)2, and Fv fragments;
- c) optionally, a protein or polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, an amino acid sequence having at least 90% homology to SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10, or a functional fragment of an amino acid sequence as set forth in SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10;
- optionally, a second RVFV-specific immunoreagent selected from the group consisting of monoclonal antibody, antibody from polyclonal sera, Fab, F(ab′)2, and Fv fragment, which second RVFV-specific immunoreagent specifically binds to a protein or polypeptide of (c);
- e) a container;
- f) one or more buffers;
- and
- g) instructions.
Dependencies are inferred from the claim text.